Skip to content
Film Television Auditions – Lifestyle
Author:
Boehringer Ingelheim Limited
Sustained health equity progress lifts Boehringer to rank 6th in Access to Medicine Index
November 10, 2026
CVMP adopts a positive opinion for SCOVELLA®, the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
November 10, 2026
Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits
November 9, 2026
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
November 4, 2026
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
October 30, 2026
Boehringer Ingelheim Establishes Metabolic Matters Steering Committee to Advance More Connected Care for Obesity and Related Liver Diseases
October 28, 2026
Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development
October 22, 2026
Boehringer Ingelheim’s New Quarterable Snap-Tab PREVICOX® (firocoxib) Chewable Tablets Provide Flexible Dosing for Dogs in the U.S.
October 7, 2026
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
October 1, 2026
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
September 29, 2026
1
2
3
Next Page
→